Tvardi Therapeutics, Inc. (TVRD)
Healthcare · NCM
Fundamentals
Valuation and ratings
Tvardi Therapeutics, Inc. trades at USD2.51, which is 38% above the USD1.55 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 10 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
TVRD earnings and analyst estimates
Recommendation mix, 9 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
TVRD passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
4 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- David Greenspan, Slate Path Capital LP$2.24M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$292.9K · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$134.2K · 0.0% of book
- Farallon Capital, FARALLON CAPITAL MANAGEMENT, L.L.C.$68.2K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Tvardi Therapeutics, Inc. (TVRD) undervalued?
Against our discounted cash flow estimate of USD1.55, TVRD at USD2.51 is 38% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
Which funds own TVRD?
4 of the institutions we track reported a position in TVRD in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
When does TVRD report earnings next?
Tvardi Therapeutics, Inc. is scheduled to report on 13 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for TVRD, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.